Accelerating Drug Translation

Abstract excerpt

There is an unmet need for new pathways to evaluate therapeutic targets and drugs for coronary artery disease (CAD). The use of major adverse cardiovascular events as a primary outcome is advantageous for rigor, but challenges related to large sample size requirements, long study durations, and associated costs and risks remain major disincentives for key stakeholders. Until now, a robust, well-validated...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cardiac Imaging and Diagnostics
• Share to Coronary Interventions and Diagnostics
• Share to Lipoproteins and Cardiovascular Health